Publication
Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.
Shuhan Zhao, Jing Tang, Xin Li, Tao Yin, ShanMiao Gou, Jing Wang, Zhenyu Lin, Jianli Hu, Hongli Liu, Xiaoxue Gou, Heshui Wu, Tao Zhang, Jun Xue
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: Optimal neoadjuvant therapy for borderline resectable pancreatic cancer/locally advanced pancreatic cancer (BRPC/LAPC) remains undefined. This study evaluated the efficacy and safety of neoadjuvant nab-paclitaxel and gemcitabine plus camrelizumab, with or without early stereotactic body…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Pancreatic Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available